Imaging company IPOs today; Shareholder tries to block Covidien-Medtronic deal;

@FierceMedDev: Boston Scientific wins expanded European approval for Lotus transcatheter valve system. Article | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Placenta plays vital role in fetal development, but much remains in the way of medical breakthroughs and research. More from the NYT | Follow @EmilyWFierce

> Florida-based imaging company iRadimed hopes the IPO that debuted today will pull in $12.6 million towards their non-magnetic infusion pumps. Story

> The FDA is searching for new ways to promote pediatric devices. Story

> A Covidien ($COV) shareholder yesterday filed a class action lawsuit in an attempt to block the company's upcoming takeover by Medtronic ($MDT). Story

Biotech News

@FierceBiotech: ICYMI yesterday: Three more biotechs target $175M in IPO cash amid market tumult. Report | Follow @FierceBiotech

@DamianFierce: A+ photo choice. It's like he's snatching the savings right outta your hand. More from the WSJ | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday, check out the latest issue of FierceBiotech Research. Report | Follow @EmilyMFierce

> Roche is at an Alzheimer's crossroads after mixed data for AC Immune's drug. Story

> 'Economic patriotism' could dampen biopharma's M&A boom. Article

> Cancer vaccine maker immatics adds nearly $30M in Series D. News

> GlaxoSmithKline and Theravance eye Phase III for another COPD contender. Article

> Immunocore and Lilly strike a risk-sharing deal in oncology R&D. News

Pharma News

@FiercePharma: Top-read on FP Tuesday: J&J's powerhouse drug launches drive 21% boost to Q2 pharma sales. Story | Follow @FiercePharma

@EricPFierce: GSK investing $25M in Codexis technology as it looks for 'more elegant' ways to manufacture APIs. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Merck is aiming to revive Zilmax sales, but it's not that easy after safety scare. Article | Follow @CarlyHFierce

> Pfizer amps up its 'Get old' campaign with more content, more social media. Item

> Reuters: Sanofi in $8.5B sell-off talks with Mylan, Abbott, private equity. Report

> Sanofi and others hit hard by India's price caps on heart and diabetes drugs. More

> Ex-China staffers sue GSK for 'illegal' termination amid bribery scandal. Report

Drug Delivery News

> Boston Scientific wins CE mark for 25-mm drug-eluting Lotus Transcatheter Aortic Valve. Item

> UPenn researchers develop nanogel for mitigating lung inflammation. Report

> Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer. More

> Delivering breast cancer drug through the skin grants disease prevention. Article

> Nasal version of naloxone for opioid overdose gets on FDA's fast track. Story

Diagnostics News

> Asuragen gains New York state's OK to launch autism and thyroid tests. More

> Roche and Merck KGaA team on a multicancer companion diagnostic test. Story

> MGC Diagnostics grows international reach with Belgian M&A deal. News

> NeuroVision Imaging's CEO discloses approval timeline for eye test to help spot Alzheimer's. Report

> Maryland researchers expand usefulness of schizophrenia biomarker found in saliva. Article

Pharma Marketing News

> J&J's new hep C med Olysio aced Q2. So why are investors worried? More

> Orphan drug approvals are up, but prices are up more. Report

> Afraid of aging? Pfizer's revamped 'Get old' campaign wants you. Story

> In social media, what's easier to grasp--an FDA webinar or an FDA warning letter? More

> Roche's Avastin steps on FDA fast track for new cervical cancer use. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.